Knockdown of PGM1 Synergistically Enhances Anticancer Effects of Orlistat in Gastric Cancer Under Glucose Deprivation

Bo Cao  
Chinese PLA General Hospital

Huan Deng  
Chinese PLA General Hospital

Hao Cui  
Chinese PLA General Hospital

Ruiyang Zhao  
Chinese PLA General Hospital

Hanghang Li  
Chinese PLA General Hospital

Bo Wei  
Chinese PLA General Hospital

Lin Chen (chenlinbj@sina.com)  
Chinese PLA General Hospital  https://orcid.org/0000-0001-6245-8509

Primary research

Keywords: Gastric cancer, Phosphoglucomutase 1, Orlistat, Glucose deprivation, Cancer metabolism, Apoptosis

DOI: https://doi.org/10.21203/rs.3.rs-650761/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Phosphoglucomutase 1 (PGM1) acts as an important regulator in glucose metabolism. However, the role of PGM1 in gastric cancer (GC) remains unclear. This study aims to investigate the role of PGM1 and develop novel regimens based on metabolic reprogramming in GC.

Methods

Correlation and enrichment analysis of PGM1 was conducted based on The Cancer Genome Atlas database. Data derived from the Kaplan-Meier Plotter database were analyzed for correlations between PGM1 expression and survival time of GC patients. CCK-8, EdU, flow cytometry assays, generation of subcutaneous tumor and lung metastasis mouse models were used to determine growth and metastasis in vitro and in vivo. Cell glycolysis was detected by a battery of glycolytic indicators, including lactate, pyruvic acid, ATP production and glucose uptake. Fatty Acid Synthase (FASN) activity and detection of lipid regulators levels by western blot were used to reflect on the cell lipid metabolism.

Results

Correlation and enrichment analysis suggested that PGM1 was closely associated with cell proliferation and metabolism. PGM1 was overexpressed in GC tissues and cell lines. High PGM1 expression served as an indicator of shorter survival for specific subpopulation of GC patients, which was also correlated with some clinicopathological features, including T stage and TNM stage. Under low glucose conditions, knockdown of PGM1 significantly suppressed cell proliferation and glycolysis levels, whereas lipid metabolism was enhanced. Orlistat, as a drug that was designed to inhibit FASN activity for obesity treatment, effectively induced apoptosis, suppressed FASN activity. However, orlistat conversely increased glycolytic levels in GC cells. Orlistat exhibited more significant inhibitive effects on GC progression after knockdown of PGM1 under glucose deprivation due to combination of glycolysis and lipid metabolism.

Conclusions

Downregulation of PGM1 expression under glucose deprivation synergistically enhanced anti-cancer effects of orlistat. This combination application may serve as a novel strategy for GC treatment.

Background

Gastric cancer (GC) is one of the most malignant tumors worldwide. The latest investigation of global cancer statistics showed that there were over 1,000,000 new cases of GC and that GC caused an estimated 769,000 deaths in 2020; thus GC ranks fifth in incidence and fourth in mortality[1]. Despite advancements in surgical techniques and chemotherapeutic regimens, many patients with advanced or late-stage GC still have poor prognosis. How to effectively inhibit GC progression is the hot topic of current medical research. In recent years, targeted drugs have attracted much attention and significantly
improved therapeutic regimens. However, the subpopulation that can potentially harvest benefits from targeted drugs is limited and the associated medical costs are relatively high. It is eagerly required to develop drugs that can be widely applied and simultaneously have high efficacy.

Metabolic reprogramming is a hallmark of cancer cells, and can provide sufficient energy and substances to allow adaptation to the highly proliferative state[2]. This universal characteristic determines that most of cancers can be effectively attenuated by metabolic inhibition. The critical molecules of glycolysis were gradually identified and inhibition of them has been proved as an effective approach of cancer treatment[3]. However, unlike in-vitro environments, tumors usually survive in a glucose-deprived microenvironment, Glucose starvation exerts stress to cancer cells and reprograms glycolysis and alternative pathways to cope with harsh conditions. Metabolic compensation may be an important reason that glycolysis inhibition cannot thoroughly eliminate cancer cells in vivo. Lipids serve as the important energy source during nutrient deprivation. Many rate-limiting enzymes and regulators in lipid metabolism are abnormally expressed and participated in carcinogenesis [4, 5]. Inspired by this cue, researchers investigated potential value of current metabolism drugs. Orlistat, a type of fatty acid synthase (FASN) inhibitor, is preliminarily used for weight loss. Numerous studies revealed its anticancer efficacies and set the potential value of clinical therapy[6-8].

Phosphoglucomutase 1 (PGM1) is the enzyme involved in glycogen metabolism. It reversibly converts glucose-1-phosphate to glucose-6-phosphate. The critical role of PGM1 in regulating glucose metabolism and cancer progression in several types of cancer were reported [9, 10]. The functions of PGM1 in GC development is still unclear. In this study, we found that decreasing PGM1 expression attenuated GC proliferation and glycolysis under glucose deprivation. Orlistat effectively induced apoptosis and suppressed FASN activity. Importantly, PGM1 expression downregulation enhanced the anticancer effects of orlistat through synergistical inhibition of glucose and lipid metabolism. Our findings suggested that combinational suppression of glucose and lipid metabolism may serve as a promising strategy for GC treatment.

Methods

Correlation and enrichment analysis

Profiles of gene expression in GC tissues were downloaded from The Cancer Genome Atlas database. Pearson correlation analysis was performed to screen the 600 genes that were most positively or most negatively associated with PGM1 expression. The 600 candidate genes were selected for enrichment analysis for identification of PGM1 functions. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was conducted based on the clusterProfiler R software package R.

Clinical specimen

A total of 40 pairs of GC tissues and corresponding adjacent noncancerous tissues were collected from patients who underwent gastrectomy at Chinese PLA General Hospital from March 2020 to October 2020.
Pathological examinations were performed by two independent pathologists. This study was approved by the Ethical Committee of Chinese PLA General Hospital. Informed consent was obtained from included patients.

**Cell culture**

GC cell lines (BGC-823, MKN-28, MGC-803, SGC-7901, HGC-27 and AGS), a human gastric epithelial cell line (GES-1) and a human embryonic kidney cell line (HEK-293T) were purchased from American Type Culture Collection (MD, USA). BGC-823 cells stably carrying luciferase (luc-BGC-823) were previously established and stored in our laboratory. Cells were grown in high-glucose Dulbecco's modified Eagle's medium (DMEM, Thermo Fisher, Waltham, MA, China) supplemented with 10% fetal bovine serum (FBS, Kangyuan Biotech, Tianjin, China) unless otherwise indicated. Cells were cultivated in an incubator at 5% CO₂ atmosphere and 37°C. The low-glucose (LG) medium comprised of glucose-free DMEM (Thermo Fisher) supplemented with 10% FBS and 2.5 mM glucose. The normal-glucose (NG) medium contained glucose-free DMEM, 10% FBS and 10 mM glucose[11].

**shRNA transfection and lentivirus infection**

An shRNA against PGM1 was designed and synthesized by JTS Scientific (Wuhan, China). Transfection with PGM1 shRNA was performed using Lipofectamine 3000 (Thermo Fisher) according to the manufacturer's protocol. To establish cell lines with stable knockdown of PGM1, a lentiviral packaging kit (Yeasen, Shanghai, China) was used to produce lentivirus media for cell infection. BGC-823 and MKN-28 cells were seeded at the appropriate density and then treated with lentivirus for 24 h. 5 mg/mL puromycin was then added into medium to conduct chemical selection and exclude uninfected cells.

**Quantitative real-time PCR (qRT-PCR) analysis**

Total RNA was extracted from clinical specimens using TRIzol Reagent (Invitrogen, NY, USA). ExScript RT-PCR kit (TaKaRa, Japan) was used to perform reverse transcription. Then, cDNA was amplified using SYBR Premix Ex Taq II (TaKaRa) and Archimed X4 system (RocGene, Beijing, China). $2^{-\Delta\Delta Ct}$ methods was employed to calculate relative expression of target genes. b-actin served as the internal control gene. The primers for PGM1 were 5'- CGACTCCTTTACCGGAACTCA-3' (forward) and 5'-TCCAGTGGTTTGGCGAAT-3' (reverse). The primers for b-actin were 5'- TCGTGCGTGACATTAAGGAG-3' (forward) and 5'- ATGCCAGGGGTACATGGTGGT-3' (reverse).

**Western Blot (WB) analysis**

For the preparation of WB samples, cells were harvested and lysed in radio immunoprecipitation assay (RIPA) buffer (Solarbio, Beijing, China). Cell debris was removed by centrifugation. Protein quantification was conducted using BCA Protein Assay Kit (Thermo Fisher). SDS loading buffer (Solarbio) was added to the protein supernatants, which were then heated at 100°C for 15 min. Equal amounts of protein were separated by SDS-PAGE and transferred onto polyvinylidene fluoride membranes (Millipore, MA, USA).
The membranes were blocked using 5% skim milk at room temperature for 1 h. The primary and secondary antibodies used in this study were purchased from Abcam (Cambridge, UK). The membranes were incubated with primary antibodies overnight at 4 °C and secondary antibodies at room temperature for 1 h. The blots were imaged using ECL Western Blotting Substrate (Solarbio) and a WB imaging system (Tanon, Beijing, China).

**Cell counting kit-8 (CCK-8) assay**

CCK-8 assay (Abmole Bioscience, Shanghai, China) was used to measure GC proliferation in vitro. At the indicated time, the complete medium used for cell cultivation was removed, and 10% CCK-8 solution diluted by the FBS-free medium was added into wells. The plates were incubated at 37°C for 1 h protected from light. The absorbance of the CCK-8 solution at 450 nm was measured by a microplate reader (Biotek, VT, USA).

**5-Ethynyl-2-deoxyuridine (EdU) assay**

The EdU assay is another approach to measure the proliferative capability of cells. Cell Proliferation EdU Image Kit was purchased from Abbkine (Wuhan, China). The experiments were performed according to the manufacturer’s protocol. The nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, Abbkine) to determine the total number of cells. Fluorescent images were observed under the fluorescence microscope.

**Metabolic experiments**

To investigate glycolysis levels in GC, Lactate Colorimetric Assay Kit II, Pyruvate Colorimetric/Fluorometric Assay Kit, ATP Colorimetric/Fluorometric Assay Kit and Glucose Uptake Colorimetric Assay Kit (Biovision, CA, USA) were used according to the manufacturer's protocols. Measurement of FASN activity was conducted using FASN Activity Kit (Solarbio). Absorbance was measured using the microplate reader as indicated by the corresponding protocols.

**Cell apoptosis assay**

Cells were harvested and washed with cold phosphate-buffered saline. FITC Annexin V Apoptosis Detection Kit 1 (BD Pharmingen, NJ, USA) was used to stain cells and detect apoptosis induced by orlistat. Apoptotic cells were detected by a FACSort Flow Cytometer (BD Pharmingen). Cells that were Annexin V- and propidium iodide (PI)- positive were regarded as late apoptotic cells. Annexin V-positive but PI-negative was the hallmark of early apoptosis. Living cells were negative for both Annexin V and PI.

**Animal experiment**

In vivo experiments were conducted to further validate the efficacy of PGM1 knockdown and orlistat treatment. Four-week-old male nude mice were purchased from Charles River (Beijing, China) and housed under specific pathogen-free conditions. To generate mouse models with subcutaneous cancer, a total of
5×10^6 luc-BGC-823 cells were subcutaneously injected into the nude mice. The longest and shortest diameters were determined using a vernier caliper every 5 days. Tumor volume = \( \frac{\text{longest diameter} \times \text{shortest diameter}^2}{2} \). For evaluation of metastatic capability, 2×10^6 luc-BGC-823 cells were suspended in phosphate buffer saline (PBS, Solarbio) and injected into tail veins of nude mice. One week after construction of the two models, mice were treated with 240 mg/g of orlistat or the corresponding solvent daily by intraperitoneal injection. After 30 days, the mice were intraperitoneally injected with 1.5 mg D-luciferin (Solarbio) dissolved in PBS and imaged using an in vivo imaging system (PerkinElmer, USA). To achieve euthanasia of the nude mice, they were placed in the chamber without CO2 addition. After 5 minutes of environment adaptation, CO2 was injected at the speed of 5 L/min, which was calculated as 20% volume of the chamber per minute. When cardiac arrest of all mice was observed, they were maintained in the chamber for additional 2 minutes and regarded as dead.

**Statistical analysis**

SPSS 25.2 and Prism 7.0 were used to conduct statistical analysis. The data was presented as mean±SD. Two-sided Student’s t test and one-way ANOVA were used to compare variables between groups. Survival analysis was performed by Kaplan-Meier method. Chi-square test was used to examine the correlation between PGM1 expression and clinicopathological characteristics. The experiments were performed least in triplicate unless otherwise indicated. \( P \leq 0.05 \) was regarded as the statistical significance.

**Results**

**PGM1 expression is negatively correlated with survival outcome of GC patients and overexpressed in GC**

To investigate the role of PGM1 in GC, we analyzed the correlation between PGM1 expression and the survival time of GC patients based on the Kaplan-Meier plotter database (kmplot.com/analysis)[12]. We found that patients with GC at stage III (Fig. 1a, b), simultaneously with higher expression of PGM1, had significantly shorter overall survival (OS) and progression-free survival (PFS). Patients with poorly differentiated GC (Fig. 1c) and intestinal type of GC in the PGM1-high group had lower OS (Fig. 1e). However, there was no significant difference of PFS between PGM1-high and PGM1-low groups (Fig. 1d, f). Next, we measured PGM1 mRNA expression in 40 pairs of GC and adjacent noncancerous tissues. The results showed that PGM1 was overexpressed in GC (Fig. 1g). The clinicopathological features were then analyzed and PGM1 expression was correlated with T stage and TNM stage of GC patients (Table.1). PGM1 also upregulated in GC cell lines, especially in BGC-823 and MKN-28, compared to the gastric epithelial cell line GES-1 (Fig. 1h). Collectively, PGM1 is overexpressed in GC tissues and correlated with poor prognosis of specific subpopulation of GC patients.

**Correlation and enrichment analysis of PGM1**

To further investigate the functions of PGM1 in GC progression, we employed TCGA database and screened 600 genes that were most positively or negatively associated with PGM1 expression,
respectively. The top 40 of them were displayed by heatmap (Fig. 2a). These 600 genes were enriched and analyzed by GO and KEGG analysis. GO analysis is divided into three terms, including biological process (BP), cellular component (CC) and molecular function (MF). The top 10 enriched pathways in each term were listed. The results suggested that PGM1 mainly regulated proliferation-related signaling pathways. Most of them were concerned with mitosis and substance preparation for cell proliferation (Fig. 2c-e). KEGG network indicated that PGM1 expression was closely correlated with glycometabolism and lipid metabolism. Otherwise, pathways of spliceosome and drug metabolism were also enriched (Fig. 2b). Collectively, PGM1 expression is associated with cell proliferation and metabolism of GC.

Knockdown of PGM1 attenuates the proliferation under glucose deprivation

Since the close association between PGM1 expression and GC development, we next explored the oncological functions. BGC-823 and MKN-28 cells were selected for further experiments due to their high expression of PGM1. A shRNA targeting PGM1 and the corresponding overexpression plasmids were synthesized. BGC-823 and MKN-28 cells were infected with lentivirus carrying shRNA targeting PGM1. The regulatory effects of the shRNA and additional transfection of overexpression plasmids on PGM1 expression were examined by WB analysis (Fig. 3a). CCK-8 assay demonstrated that PGM1 knockdown only slightly decreased cell proliferation under NG conditions in BGC-823 and MKN-28 cells and that this decrease was not significant. However, when cells were cultivated in LG medium, PGM1 expression downregulation significantly attenuated cell proliferation. To assess the off-target effects of the shRNA, we restored PGM1 expression by additional transfection of PGM1 overexpression plasmids, which rescued the proliferation of GC cells (Fig. 3b-e). The results suggested that the shRNA targeting PGM1 had no off-target effects on proliferation. The PGM1-mediated regulation of GC proliferation was also confirmed by the EdU assay (Fig. 3f, g). The results suggested that PGM1 expression downregulation could suppress tumors under glucose deprivation in vitro.

Altered PGM1 expression affects glucose and lipid metabolism under glucose deprivation

Since the close relationship between PGM1 and glucose metabolism, we aimed to explore the alterations in glycolysis levels after PGM1 knockdown. Lactate, pyruvic acid, and ATP are important metabolites. Glucose uptake is the first step of glucose metabolism. We found that PGM1 knockdown in NG medium led to mild increases in lactate, pyruvic acid production and glucose uptake, but there was no significant change in ATP production. These results showed that suppression of PGM1 under glucose-sufficient conditions could not effectively affect the energy supply in GC cells. However, sharp decreases in the lactate, ATP, pyruvic acid production and glucose uptake were observed after knockdown of PGM1 under LG conditions (Fig. 4a-d). The data proved that PGM1 acted as a critical role in maintaining glycolysis under LG conditions.

Next, we investigated lipid metabolism regulated by PGM1 and glucose supply. WB analysis was used to measure the expression of FASN, Carnitine Palmitoyltransferase 1A (CPT1A) and Acetyl CoA Carboxylase (ACC) in lipid metabolism. FASN, CPT1A and ACC were mostly upregulated after PGM1 knockdown under LG conditions (Fig. 4e). FASN biological activity in BGC-823 and MKN-28 was also enhanced (Fig. 4f).
Collectively, the results suggested that PGM1 could regulate the balance between glycolysis and lipid metabolism. PGM1 expression downregulation suppressed glycolysis levels and facilitated lipid metabolism in GC cells under LG conditions.

**Orlistat inhibits lipid metabolism but promotes glycolysis in GC.**

Orlistat was initially designed to suppress lipid metabolism for weight loss. Specifically, it was proven to bind to the structural domain of FASN and reduce the activity of FASN[13], which is one of the mechanisms by which orlistat inhibits tumor growth[6, 14]. However, few studies focused on FASN functions in GC and the effects of orlistat on GC metabolism remains unclear. To confirm the role of orlistat in GC therapy, we treated BGC-823 and MKN-28 cells with 0, 20, 40, 60 mM orlistat. FASN, CPT1A and ACC expression levels were reduced (Fig. 5a) and FASN biological activity was also inhibited with increasing concentration of orlistat (Fig. 5b). Surprisingly, we found that orlistat reversely increased lactate, ATP, pyruvic acid production and glucose uptake (Fig. 5c-f). These results revealed that orlistat treatment inhibited lipid metabolism, whereas promoted glycolysis levels in GC cells.

**PGM1 expression downregulation enhances orlistat-induced apoptosis under glucose deprivation**

We next investigated anti-cancer effects of orlistat in GC. Flow cytometry assay demonstrated that orlistat treatment led to apoptosis of BGC-823 and MKN-28 cells and that there was a significant dose-effect relationship (Fig. 6a). Since the complementary roles of orlistat and PGM1 knockdown in metabolic regulation, it was speculated that PGM1 expression downregulation can reverse the enhancement of glycolysis caused by orlistat under LG conditions, which may lead to the sensitization to orlistat in GC cells. Data showed that under LG conditions, PGM1 knockdown induced cell apoptosis. The anticancer effects of orlistat were significantly augmented after PGM1 knockdown compared to the group of single treatment of it. Our findings suggested that PGM1 expression downregulation enhanced the effects of orlistat, possibly through attenuating both glucose and lipid metabolisms, impairing the energy compensation caused by the single factor.

**The combination of orlistat and PGM1 expression downregulation suppresses tumor growth and metastasis in vivo**

To promote the clinical translation of this regimen, we generated nude mice with subcutaneous tumors and lung metastasis. The volumes of the tumors derived from luc-BGC-823 cells with stable PGM1 knockdown were smaller than those derived from the control group. Treatment with orlistat could also decrease the tumor burden. Combination of the two approaches achieved better efficacies than either approach alone (Fig. 7a-c). For the metabolic alterations, PGM1 expression downregulation suppressed lactate production and facilitated FASN activity in tumor tissues. Orlistat treatment showed the opposite effects. Combination use led to simultaneous attenuation of lactate production and FASN activity (Figure 7d, e). Similar with the results of subcutaneous cancer, the metastatic capability was also suppressed by PGM1 knockdown and orlistat treatment. The effects of orlistat on metastasis suppression were enhanced after knockdown of PGM1 expression. In summary, our findings revealed a novel therapeutic
regimen for GC (Figure 7f, g). Orlistat could effectively induce cancer cell apoptosis and PGM1 knockdown under glucose deprivation enhanced this anticancer effect in vitro and in vivo by synergistically inhibiting the glucose and lipid metabolism.

**Discussion**

Cancer cells universally undergo reprogramming of glucose and lipid metabolisms, which can provide energy supply to support the proliferative state and resist against harsh environments. These two metabolic pathways are both activated and regulated by many oncogenes in GC[15–17]. Inhibiting critical targets of cell metabolism effectively suppresses malignant behaviors and become a novel strategy of cancer treatment[18, 19]. Some small-molecule inhibitors that were originally developed for treatment of metabolic diseases have exhibited potentials in cancer inhibition[11, 20]. However, many studies focused on only one type of metabolism. Inhibiting one metabolic pathway might not be fully efficacious in clinical practice due to the compensation of other metabolic pathways. Importantly, glucose deprivation is one of the features of the microenvironment where tumors grow in vivo. An alteration in glucose concentration can drive cancer cells to regulate intracellular signaling pathways and depend on other energy sources[21, 22]. The evidence proved that cancer cells actively undergo metabolic reprogramming to adapt to nutrient starvation and environmental stress.

PGM1 reversibly regulates the catabolism and anabolism of glycogen under physiological conditions[23]. Deficiency of PGM1 expression during embryonic development can lead to inherited metabolic disorders[24]. PGM1 was also reported to promote progression in lung and ovarian cancer[9, 10]. We noticed that PGM1 inhibited malignant progression of hepatocellular carcinoma[25], which seems to contradict conclusions of other studies. The inconsistence may result from differences in cancer types or cultivation conditions. The role of PGM1 in GC has not been clearly identified. In this study, qPCR and WB analysis showed that PGM1 expression was upregulated in GC tissues and cell lines. The positive correlations between PGM1 expression and T stage and TNM stage were also observed in the included patients. The data from the Kaplan-Meier Plotter database showed that higher PGM1 expression was correlated with poor prognosis of patients with GC at stage III, poorly differentiated GC, or the intestinal type of it. PGM1 had great potentials as a diagnostic biomarker and prognostic factor.

The enrichment analysis was conducted to investigate the functions and signaling pathways of PGM1. PGM1 was associated with cell proliferation and metabolism. It suggested that PGM1 might regulate GC growth through metabolic reprogramming. The experiments both in vitro and in vivo were performed. Consistent with previous studies[9, 10], downregulation of its expression significantly inhibited cancer progression under glucose deprivation conditions. For metabolic alterations, PGM1 knockdown led to suppression of glycolysis, while lipid metabolism was moderately enhanced. This metabolic conversion might be explained by the compensatory effects of lipid metabolism under nutrient-insufficient conditions.
Orlistat is a classical inhibitor of FASN and has exhibited its anti-cancer effects recently in the past decade. Chuang et al revealed that orlistat sensitized prostate cancer to radiotherapy via FASN/NF-κB pathway[14]. Almeida et al constructed mouse models of spontaneous melanoma metastasis. They reported that orlistat attenuated metastatic capability of melanoma cell lines and activated immune response[26]. Our findings proved that treatment with orlistat reduced lipid metabolism in GC cells. There were significant dose-dependent effects on orlistat-induced apoptosis. Interestingly, glycolytic levels were increased after orlistat treatment. Accumulating evidence indicated that glycolysis enhanced drug resistance and cancer survival[27, 28], which may be one of the reasons that impairs effectiveness of orlistat. Considering the complementary functions of PGM1 and orlistat, we speculated that PGM1 knockdown could enhance orlistat efficacy by synergistic suppression of glucose and lipid metabolism. The results showed that PGM1 knockdown under LG conditions enhanced apoptosis induced by orlistat in GC cells. Similarly, in vivo experiments indicated that PGM1 knockdown or orlistat treatment decreased GC growth and metastasis. The combinational regimen outperformed the single approach and synergistically inhibited glucose and lipid metabolism.

However, there are some limitations in this study. We solely focused on the relationships between metabolism and cancer progression. The mechanisms by which this combinational regimen inhibited GC and metabolic pathways are still unclear. The potential off-target effects of orlistat need further exploration. Clinical trials are also required to confirm the value of this regimen in GC treatment.

Conclusion

Taken together, our findings identified the oncogenic role of PGM1 in GC for the first time, and validated that PGM1 has the potential for GC diagnosis and prognostic prediction. Combination of PGM1 knockdown and orlistat treatment was proposed based on the complementary mechanisms in metabolic reprogramming. Orlistat treatment combined with inhibition of PGM1 effectively suppressed GC growth and metastasis both in vitro and in vivo. This strategy provides a novel insight for the development of anti-metabolic therapy.

Abbreviations

GC: gastric cancer; PGM1: Phosphoglucomutase 1; FASN: Fatty Acid Synthase; CPT1A: Carnitine Palmitoyltransferase 1A; ACC: Acetyl CoA Carboxylase; TCGA: CCK-8: cell counting kit-8; GO: Gene ontology; BP: biological process; CC: cellular component; MF: molecular function; KEGG: Kyoto Encyclopedia of Genes and Genomes; EdU: 5-Ethynyl-2-deoxyuridine; qRT-PCR: quantitative real-time PCR; WB: western blot; OS: overall survival; PFS: progression-free survival; NC: negative control; NG: normal glucose, 10 mM glucose in medium; LG: low glucose, 2.5 mM glucose in medium; DMSO: dimethyl sulfoxide.

Declarations
Ethics approval and consent to participate

The use of clinical specimens and clinicopathological information was approved by the Ethical Committee of Chinese PLA General Hospital. Informed consent was obtained from included patients. All animal experiments conformed to the internationally accepted principles for the care and use of laboratory animals.

Consent for publication

Not applicable

Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This research was funded by National Natural Science Foundation of China (No. 81972790 and 81773135).

Conflicts of interest/Competing interests

There is no conflict of interest in this research.

Authors’ contributions

Cao B, Deng H and Cui H performed the experiments and acquired data; Deng H, Zhao RY and Li HH analyzed and interpreted the data; Cao B, Cui H and Wei B wrote the manuscript; Wei B and Chen L revised the manuscript and checked the data; Chen L designed the study and arranged the experiments. All authors approved the final version of the article.

Acknowledgements

Not applicable.

References


Tables
Table 1 Correlation between PGM1 expression and clinicopathological characteristics of 40 GC patients.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Case number</th>
<th>High (n=20)</th>
<th>Low (n=20)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at surgery (years)</td>
<td>0.749</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>23</td>
<td>11</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>≥60</td>
<td>17</td>
<td>9</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>0.288</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>29</td>
<td>13</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>11</td>
<td>7</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>T stage</td>
<td>0.038</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1+T2</td>
<td>13</td>
<td>3</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>T3+T4</td>
<td>27</td>
<td>17</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>0.337</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5</td>
<td>23</td>
<td>10</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>≥5</td>
<td>17</td>
<td>10</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Location</td>
<td>0.749</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td>17</td>
<td>9</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Non-cardiac</td>
<td>23</td>
<td>11</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td>0.025</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I+II</td>
<td>17</td>
<td>5</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>III+IV</td>
<td>23</td>
<td>15</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Differentiation</td>
<td>0.230</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poorly</td>
<td>37</td>
<td>20</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

Figures
PGM1 expression is negatively correlated with survival outcome of GC patients and overexpressed in GC. (a, b) OS (a) and PFS (b) of GC patients at III stage who were divided into low-PGM1 and high-PGM1 groups according to the Kaplan-Meier plotter database. (c, d) OS (c) and PFS (d) of patients with poorly differentiated GC who were divided into low-PGM1 and high-PGM1 groups according to the Kaplan-Meier plotter database. (e, f) OS (e) and PFS (f) of patients with the intestinal type of GC who were divided into low-PGM1 and high-PGM1 groups according to the Kaplan-Meier plotter database.
low-PGM1 and high-PGM1 groups according to the Kaplan-Meier plotter database. g qRT-PCR analysis to analyze PGM1 mRNA expression in 40 pairs of GC and adjacent noncancerous tissues. h WB analysis to show the PGM1 expression between GC and gastric epithelial cell lines. Data are shown as the mean ± SE. **P < 0.01.

Figure 2

Correlation and enrichment analysis of PGM1. a The relative expression of PGM1 in GC tissues from TCGA database were shown above, which were divided into low and high groups according to the median expression. Top 20 genes that most positively associated with PGM1 expression and top 20 genes that most negatively associated with it were displayed below. b KEGG network to display top 10 pathways associated with PGM1 expression. c top 10 BP terms that were significantly enriched in KEGG analysis. d
top 10 CC terms that were significantly enriched in KEGG analysis. e top 10 MF terms that were significantly enriched in KEGG analysis.

Figure 3

Knockdown of PGM1 attenuates the proliferation under glucose deprivation. a WB analysis to show the PGM1 expression in BGC-823 and MKN-28 cells stably carrying PGM1 shRNA or scrambled shRNA and additional transfection of PGM1 overexpression plasmids or vectors, respectively. b, c CCK-8 assay to
measure proliferation of BGC-823 (b) and MKN-28 cells (c) as in (a) under NG conditions. d, e CCK-8 assay to measure proliferation of BGC-823 (d) and MKN-28 cells (e) as in (a) under LG conditions. f EdU assay to measure proliferation of cells as in (b, c). g EdU assay to measure proliferation of cells as in (d, e). Histograms are on the right. Scale bar: 100 μm. Data are shown as the mean ± SE. *P < 0.05, **P < 0.01, n.s. no significant.
Altered PGM1 expression affects glucose and lipid metabolism under glucose deprivation. a-d Colorimetry assays to measure glycolysis of BGC-823 and MKN-28 cells with knockdown of PGM1 or NC under NG or LG conditions, including lactate (a), ATP (b), pyruvic acid production (c) and glucose uptake capability (d). e WB assay to show protein expressions of cells as in (a-d). f Colorimetry assay to measure FASN activity of cells as in (a-d). Data are shown as the mean ± SE. *P < 0.05, **P < 0.01, ***P < 0.001, n.s. no significant.
Orlistat inhibits lipid metabolism but promotes glycolysis in GC. a WB assay to show protein expressions of BGC-823 and MKN-28 cells after treatment of DMSO, 20 μM, 40 μM or 60 μM for 24 h. b Colorimetry assay to measure FASN activity of cells as in (a). c-f Colorimetry assays to measure glycolysis in GC cells after treatment of DMSO or 60 μM for 24 h, including lactate (c), ATP (d), pyruvic acid production (e) and glucose uptake capability (f). Data are shown as the mean ± SE. *P < 0.05, **P < 0.01, ***P < 0.001, n.s. no significant.

Figure 6

PGM1 expression downregulation enhances orlistat-induced apoptosis under glucose deprivation. a Flow cytometry to detect the apoptosis of BGC-823 and MKN-28 cells treated with DMSO, 20 μM, 40 μM or 60 μM for 24 h. b Flow cytometry to detect the apoptosis of BGC-823 and MKN-28 cells with knockdown of PGM1 or NC and treated with DMSO or 60 μM for 24 h under LG conditions. Data are shown as the mean ± SE. **P < 0.01, ***P < 0.001, n.s. no significant.
The combination of orlistat and PGM1 expression downregulation suppresses tumor growth and metastasis in vivo. a Representative bioluminescence images at 30 days after subcutaneous injection of luc-BGC-823 cells with knockdown of PGM1 or NC and treated with 240 mg/g of orlistat or the corresponding solvent daily. b Curves of tumor volumes as in (a) at the indicated time. c Luminescence signals in (a) represented by overlaid false-color images with the signal intensity. d Lactate production

Figure 7
was determined in the tumor tissues from (a). e FASN activity was determined in the tumor tissues from (A). f Representative bioluminescence images at 30 days after tail vein injection of luc-BGC-823 cells with knockdown of PGM1 or NC and treated with 240 mg/g of orlistat or the corresponding solvent daily. g Luminescence signals in (f) represented by overlaid false-color images with the signal intensity. Data are shown as the mean ± SE. *P < 0.05, **P < 0.01, ***P < 0.001.